Latest News

Genetic evidence that new therapies targeting Parkinson's disease may cause harm

Researchers have completed a small study that shows genetic and clinical evidence that therapies targeting the expression of alpha-synuclein -- a gene whose function is involved in the development and progression of Parkinson?s disease -- may accelerate disease progression and increase the risk of physical incapacitation and dementia. If replicated, the findings will have profound implications for therapies under development for Parkinson?s disease.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Family criticizing your weight? You might add more pounds

  • Early exposure to antidepressants affects adult anxiety, serotonin transmission

  • Cocaine, amphetamine users more likely to take their own lives

  • New technology advances eye tracking as biomarker for brain function, recovery from brain injury

  • Tracking the eyes: The keys to consumers' plant preferences

  • Naming people, objects in baby's first year may offer learning benefits years later

  • Meth users face substantially higher risk for getting Parkinson's disease

  • First real-time mri-guided brain surgery for Parkinson's in southern California

  • How, where the brain converts external inputs into behavioral responses

  • Teen contraband smokers more likely to use illicit drugs: Study

  •